PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) is set to unveil new clinical data on its investigational therapy, CABA-201, at the American College of Rheumatology (ACR) Convergence 2024. The event will be held at the Walter E. Washington Convention Center in Washington, D.C., from November 14-19, 2024.
CABA-201 is a fully human CD19-CAR T cell therapy under investigation in several autoimmune conditions. This innovative therapy aims to selectively and temporarily deplete CD19-positive cells, potentially allowing for an “immune system reset” and lasting remission without ongoing treatment.
The presentations will include:
Oral Presentation:
- Title: Safety and Efficacy of CABA-201 in Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus
- Date and Time: November 17, 2024, 3:30 p.m. – 3:45 p.m. ET
- Presenter: Dr. David J. Chang, Chief Medical Officer of Cabaletta Bio
Poster Presentation:
- Title: Correlative Studies of CABA-201 in Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus
- Date and Time: November 16, 2024, 10:30 a.m. – 12:30 p.m. ET
- Presenter: Dr. Daniel Nunez, Director of Computational Biology at Cabaletta Bio
These presentations will provide insights into the RESET™ clinical development program, focusing on the therapy’s impact on immune-mediated necrotizing myopathy and systemic lupus erythematosus. Additional details and abstracts can be found on the ACR Convergence 2024 website, with presentation materials available on Cabaletta Bio’s website post-event.
CABA-201 is currently being evaluated across various autoimmune diseases, including systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris. This ongoing research underscores Cabaletta Bio’s commitment to advancing therapeutic options for patients with autoimmune disorders.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.